AdaptHealth Names Suzanne Foster CEO
By Ben Glickman
AdaptHealth named Danaher executive Suzanne Foster as its next chief executive, ending a nearly 10-month search for the company's next leader.
Plymouth Meeting, Pa.-based AdaptHealth, which makes at-home medical equipment and supplies, said Foster was previously president of Beckman Coulter Life Sciences, owned by Danaher. She has also held roles at Cardinal Health At-Home Solutions and Stanley Healthcare.
She will take over as CEO effective May 20.
Foster succeeds interim CEO Richard Barasch, who stepped in to lead the company after the departure of CEO Stephen Griggs in June.
AdaptHealth previously named Crispin Teufel as Griggs' successor in June. That appointment was challenged by Linde, Teufel's former employer. Linde sued Teufel to stop his move to AdaptHealth.
Barasch has continued to serve as interim CEO until a permanent successor could be appointed. AdaptHealth said Barasch would continue to serve as chairman until June 30, after which he will step down from the board.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
April 17, 2024 16:57 ET (20:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters